Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine

BIOLOGICAL2 trials

Sponsors

Novartis Vaccines

Conditions

Meningococcal DiseaseMeningococcal Meningitis

Phase 3

Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

CompletedNCT01148017

Novartis VaccinesMeningococcal Meningitis

Start: 2010-07-31End: 2013-04-30Updated: 2017-08-14

Phase 4

Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose

CompletedNCT01823536

Novartis VaccinesMeningococcal Disease

Start: 2013-05-31End: 2014-06-30Updated: 2014-08-15

Related Papers

Antibody persistence and booster response following MenACWY-CRM vaccination in children as assessed by two different assay methods.

2019-07-034 citations